IL22 and hepatocellular carcinoma: Then we explored the potential effect of IL-22/STAT3 signaling to discriminate sorafenib outcomes (non-responder or responder) in the phase 3 STORM trial comparing sorafenib with placebo as adjuvant treatment of HCC.